Press release from Companies
Publicerat: 2025-05-07 17:30:00
As communicated in the notice to the extraordinary general meeting on 28 November 2024, two proposals were submitted for a reduction of the share capital - one of which required authorization from the Swedish Companies Registration Office - as well as a proposal to amend the articles of association to implement a reverse share split. The bulletin published on 7 January 2025, shows that the resolutions were voted through. In light of the ongoing company reorganization, and in consultation with the administrator and all shareholders who voted in favour of the resolutions, the board of directors has today decided not to submit the resolutions for registration with the Swedish Companies Registration Office.
The resolution items referred to in the notice to the extraordinary general meeting published on 28 November 2024 at 22:30 (the English version) are as follows:
Item 11 - Resolution on reduction of share capital without withdrawal of shares for allocation to unrestricted equity (number 2).
Item 12 – Decision to a) amend the articles of association (number 2) and on b) consolidation of shares.
The board of directors intends, together with the administrator and the company's major shareholders, to continuously evaluate the need for the resolutions and whether they should be proposed again later.
Shares and share capital
The board's decision thus means that the registered share capital continues to amount to SEK 42,952,072,081.94244 divided into 9,337,409,114 shares, each share with a quota value of approximately SEK 0.0046.
For further information please contact:
Anna Linton, CEO of Peptonic Medical AB
E-mail: anna.linton@peptonicmedical.se
Phone: +46 70-244 92 07
About PEPTONIC medical AB
PEPTONIC medical AB (publ) is a pioneering Swedish medtech company specializing in the development and sale of clinically proven self-care products for women's intimate health. Through its brands VagiVital and Vernivia, the Company offers a broad over-the-counter portfolio of effective and gentle products designed to help women understand, treat, and prevent common medical conditions in the intimate area. Peptonic's growth strategy centers on geographic expansion, particularly in the U.S. and Europe, while continually enhancing its product portfolio through in-house development and strategic acquisitions.
The company is headquartered in Stockholm, Sweden, and operate the subsidiaries Peptonic medical Inc. and Common Sense Marketing Inc., in the U.S. Peptonic Medical was founded in 2009 and has been listed on the Spotlight Stock Market since 2014.
